Category Archives: pricing

How Gilead “Blew Out the Lights” With Sovaldi

While flipping through my emails last week, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning. Take a look:
Also posted in Marketing, Strategy | Tagged , , | Leave a comment

Germany Post AMNOG

While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established markets, such as Germany. It’s no longer sufficient to expect that regulatory data from prospective randomized clinical studies alone will be enough to convince payers to provide […]
Also posted in Europe, Guest Blog | Tagged , , , , | Leave a comment

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals. The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and […]
Also posted in Orphan Drugs | Tagged , , | Leave a comment

Market Access in Ukraine

by Lana Sinichkina  and Leonid Cherniavskyi. On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy. In line with the signed AA, the government has adopted a detailed implementation plan, which endorses for preparation and approval by the […]
Also posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Regulatory | Tagged , , , | Leave a comment
  • Categories

  • Meta